The Centers for Medicare & Medicaid Services’ (CMS’) Proposed New Rule for 2025 offers improved payments for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries.

The diagnostics company is set to benefit from increased payments.

CMS issued its solicitation as part of the 2024 Hospital Outpatient Prospective Payment System proposed rule, released late Thursday. Currently, Medicare only reimburses for radiopharmaceuticals through a packaged system, regardless of product cost, but this can create a barrier for those who need expensive newer imaging agents, experts note. 

‍

Professional associations have pushed to eliminate this obstacle by requiring CMS to reimburse for the contrast agent separately from the exam itself.

‍

Bipartisan members of Congress have proposed legislation in both chambers to potentially fix this issue. And now it appears as if they have caught Medicare’s attention.

‍

Level 2 users were alerted to LNTH's incredible progress in April when the stock was just $65. The stock hit $125/share Thursday.